西达本胺联合泼尼松、依托泊苷和沙利度胺治疗中国初治血管免疫母细胞性T细胞淋巴瘤:一项多中心II期试验
这项多中心II期试验评估西达本胺联合泼尼松、依托泊苷和沙利度胺(CPET方案)治疗中国初治血管免疫母细胞性T细胞淋巴瘤(AITL)的疗效与安全性。71例入组,51例完成8周期,总缓解率90.2%、完全缓解率54.9%,中位无进展生存期42.6个月,最常见3/4级不良事件为中性粒细胞减少(32.3%)。
要点
- 51例完成8周期CPET方案者总缓解率90.2%、完全缓解率54.9%。
- 中位随访11.4个月,51例中位无进展生存期42.6个月,中位总生存期未达到。
- 68例安全性人群中3/4级中性粒细胞减少22例(32.3%),12例治疗相关感染经抗生素治疗恢复。
核心结论
- 口服CPET方案对中国初治AITL患者是有效、可耐受且经济的选择。
研究设计与样本
- 多中心II期临床试验,入组71例中国初治AITL患者,CPET方案共8个周期。
- 主要终点为8周期后总缓解率(ORR)和完全缓解率(CR),次要终点为无进展生存期(PFS)和安全性。
- 68例接受至少1周期CPET方案者纳入安全性评估人群。
主要发现
- 51例完成8周期者的ORR为90.2%、CR为54.9%。
- 中位随访11.4个月(95%CI 9.9-17.0),51例中位PFS为42.6个月(95%CI 27.7-未达到),中位OS未达到。
- 2年PFS率为66.5%,2年OS率为82.2%。
- 最常见3/4级不良事件为中性粒细胞减少(n=22,32.3%)。
- 12例出现治疗相关感染,经抗生素治疗恢复;其他不良事件大多轻微且可逆。
关键数值与推荐
- CPET方案共8个周期,口服给药。
- 51例完成8周期者ORR 90.2%、CR 54.9%。
- 51例中位PFS 42.6个月(95%CI 27.7-未达到),中位OS未达到。
- 2年PFS率66.5%,2年OS率82.2%。
- 3/4级中性粒细胞减少22例(32.3%)。
临床怎么用
- 原文结论认为口服CPET方案是中国初治AITL有效、可耐受且经济的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma (PTCL) with a poor prognosis, and an effective first-line therapy is lacking. Chidamide is a selective histone deacetylase inhibitor and has been approved by the China Food and Drug Administration for relapsed or refractory PTCL. We conducted a multicenter phase II clinical trial combining chidamide with prednisone, etoposide, and thalidomide (CPET regimen) for a total of eight cycles in untreated AITL patients in China. The primary objectives were the overall response rate (ORR) and complete remission (CR) rate after eight cycles of the CPET regimen. The secondary endpoints were progression-free survival (PFS) and safety. Of the 71 enrolled patients, 51 completed the eight cycles of the CPET regimen. The ORR and CR of the 51 patients were 90.2 and 54.9%, respectively. After a median follow-up of 11.4 months (95% confidence interval [CI], 9.9-17.0), the median PFS of the 51 patients was 42.6 months (95% CI, 27.7-not reached) and the median overall survival (OS) was not reached. The 2-year PFS rate and OS rate were 66.5 and 82.2%, respectively. Sixty-eight patients received at least one cycle of CPET regimen and were included as the safety assessment population. The most common grade 3/4 adverse event was neutropenia (n = 22, 32.3%). Twelve patients showed treatment-related infections and recovered from antibiotic therapy; the other adverse events were mostly mild and reversible. The oral CPET regimen is an effective, tolerable, and economical choice for untreated AITL in a Chinese population. This trial was registered in www.clinicaltrials.gov as NCT03273452.
引用
- Wang Y, Zhang M, Song W, et al. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. Am J Hematol. 2022. PMID: 35170082. doi:10.1002/ajh.26499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。